Besides genetic background, environmental factors such as food ingredients and viral infections have been indicated as important and possibly decisive elements for the induction of insulin-dependent diabetes mellitus (IDDM). Our data show that diabetes development in diabetes-prone (DP)-BB rats can be delayed and prevented by prolonging the nursing period of these rats. These results provide experimental evidence strengthening human epidemiological data that the duration of exclusive breastfeeding influences diabetes development later in life.
there is no suggested mechanism by which trypsin inhibitor gene mutations could lead to the primary forms of diabetes. In support of this, we found no association of the N34S mutation of the SPINK1 gene, when compared to ethnically matched control subjects, in a large cohort of patients with Type 1 and Type 2 diabetes from both India and Germany. These results are in contrast to recent reports [4, 6] in young patients of Bangladeshi origin. A possible explanation for this discrepancy could be that there was some heterogeneity in the study populations from Bangladesh, with the possible inclusion of patients with FCPD in their cohorts. In contrast, pancreatitis was firmly ruled out as an underlying cause of diabetes in our patients with Type 1 and Type 2 diabetes.
In summary, our data indicate that SPINK1 mutations do not represent a risk factor for Type 1 or Type 2 diabetes per se in either India or Germany. SPINK1/PST1 polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. . Surprisingly, rats weaned at 40 days showed no protection against developing diabetes. These observations show that prolonging the lactation period in DP-BB rats influences diabetes development later in life. Malnutrition in the neonatal and prepubertal period of rats can reduce beta-cell function later in life [7, 8] . The fact that the rats weaned at 40 days showed a reduction in body weight and growth rate compared to their littermates, weaned at 21 days (Fig. 1b) , suggests such malnutrition. As a consequence, too long of a duration of exclusive nursing might impair the development of beta cells and subsequently the insulin secreting capacity of the pancreas. Therefore, excessive prolongation of the nursing period might, via this mechanism, annul the positive effect of prolonged nursing on diabetes development. These results indicate that in the human situation, under-nourishment of the siblings must be prevented during the period of exclusive breastfeeding.
Since our BB rats are viral antibody free, protection against diabetogenic viral infections via antibodies in the mother's milk does not play a role in our experiments.
Taken together experiments in this animal model can provide information about the mechanisms involved in the eventual prevention of diabetes development by prolonged and exclusive breastfeeding. Such experiments will provide additional experimental evidence in contribution to epidemiological data [1, 2, 3, 4, 5] on this intriguing topic. (a) Diabetes prone BB rats received exclusively mother's milk and were weaned at 21 days (■ ■; n=25), 31 days (• •; n=12) or 40 days (▲ ▲; n=11). The control group was routinely weaned at 21 days (•; n=31). *p<0.05 as compared to the control group, littermates weaned at 21 days and littermates weaned at 40 days (Log Rank test Kaplan Meijer survival curves, Chi-Square test). (b) Representative growth-curves of exclusively nursed diabetes prone BB rats weaned at different days: • •, Male rat weaned at 21 days; ■ ■, female rat weaned at 21 days; •, male rat weaned at 41 days and ■, female rat weaned at 41 days we prolonged the lactation period of DP-BB rats from 21 to 31 and 40 days of age.
Six DP-BB rat litters consisting of eight pups each and one litter of seven pups were exclusively nursed with mother's milk. We observed before that from 14 days of age pups start to nibble from the food. To ensure that the pups received only mother's milk the litters were kept in special cages, where the food was only accessible for the mother rat. At 21 days four of the pups were weaned in the litters of eight pups and three in the litter with seven pups. In four litters the remaining pups were weaned at 31 days and in three litters the pups were weaned at 40 days. In the control group, the litters were housed in conventional cages and the pups were routinely weaned at 21 days. In the control group the pups were housed in regular cages and therefore not nursed with exclusively mother's milk. The rats were followed for diabetes development and diagnosed diabetic when their blood glucose value was higher than 11 mmol/l after two consecutive measurements. In three groups we randomly selected and killed some animals just after weaning to acquire parts of the small and large intestine of the rats. These samples were taken for a pilot-experiment to another project in our department that studies the influence of duration of breastfeeding on gut development and composition of the intestinal flora in relation to the development of diabetes. In this way we randomly excluded two animals from the group exclusively nursed for 21 days, four rats exclusively nursed for 31 days and one exclusively nursed for 40 days. Throughout the study animals were treated in compliance with the 'Principles of laboratory animal care' (NIH publication no. 85-23, revised 1985) and the Dutch law on experimental animal care.
Prolonging the lactation period in DP-BB rats to 31 days reduced the onset of diabetes compared with the control group and their littermates weaned at 21 days of age (Fig. 1a,  p=0 .0148 and 0.0051 respectively, log rank test). Moreover, the incidence of diabetes at 160 days of age of the rats weaned at 31 days is significantly lower compared with the control
Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan
To the Editor: The diabetogenic agents, streptozotocin and alloxan induce insulin deficiency due to their selective pancreatic beta-cell toxicity [1] . However, there are significant species differences in the diabetogenicity of streptozotocin and alloxan [1] . While rodents are particularly prone to the diabetogenic action of these two diabetogens, humans are considered to be resistant [1] . Human pancreatic beta cells, in contrast to rodent beta cells, have been shown to be resistant to the toxic action of streptozotocin and alloxan in vitro [2, 3, 4] . RINm5F insulin-producing cells which do not constitutively express the GLUT2 glucose transporter are virtually resistant to the toxic action of streptozotocin and alloxan [5, 6] . Expression of the rat GLUT2 glucose transporter isoform rendered these cells sensitive and the toxicity of both streptozotocin and alloxan increased in parallel with the increase of the level of GLUT2 glucose transporter expression in this rat insulin-producing tissue culture cell line [5, 6] .
Recently, it has been reported that after transplantation of human pancreatic islets into nude mice, beta cells are not damaged even after injection of high doses of streptozotocin [4] or alloxan [2, 3] , while the beta cells of rat islets trans-planted concomitantly into the same animal are destroyed [2, 3, 4] .
There are different potential explanations for this observation. Human beta cells could be more resistant to the toxic action of streptozotocin and alloxan either because they express the GLUT2 glucose transporter only to a very low extent [7, 8] (1-2% of the level expression in rat beta cells), or, alternatively, because streptozotocin and alloxan, in contrast to the rat GLUT2 glucose transporter isoform, are not taken up through the human GLUT2 glucose transporter isoform into the intracellular compartment where the toxins exert their cell-death action.
We therefore cloned and expressed the human GLUT2 glucose transporter isoform, using a known methodology [5] , in RINm5F insulin-producing tissue culture cells which constitutively do not express the GLUT2 glucose transporter isoform [5, 6] .
In an experimental protocol using the MTT cytotoxicity assay [5] we could show that the toxicity of both streptozotocin and alloxan increased in dependence upon the human GLUT2 glucose transporter gene expression level in six different RINm5F cell clones (A-F), as measured by quantitative realtime PCR analyses using the Opticon real-time PCR cycler (MJ Research, San Francisco, Calif., USA) ( Table 1) . PCR was carried out with primer sets specific for human GLUT2 using SYBRGreen (Biozym, Hessisch Oldendorf, Germany) for fluorescence detection. There was a significant correlation (p<0.01; F-test) both for streptozotocin (r=0.987) and alloxan (r=0.948) between the decrease of the half maximally effective concentrations (EC 50 ) for the toxins, at which 50% of the cells died, and the increase of the human GLUT2 glucose transporter expression level (Table 1) .
A calculation of the number of human GLUT2 mRNA molecules which must be expressed in insulin-producing cells in order to reduce the EC 50 value for toxicity by 1 mmol/l showed that less GLUT2 mRNA molecules are required for this purpose in the case of the toxicity of alloxan (3331±228) than in the case of streptozotocin (4670±164). Thus, it can be concluded that the human GLUT2 glucose transporter shows an apparently greater affinity for alloxan than for streptozotocin.
For purposes of comparison, we did a comparable calculation for the rat GLUT2 transporter using data which we published earlier [5, 6] . The result shows that also in the case of the rat GLUT2 transporter, alloxan (1213±96) requires less GLUT2 mRNA molecule expression than streptozotocin (3416±358) showing that not only the human GLUT2 glucose transporter but also the rat GLUT2 glucose transporter has a greater affinity for alloxan than for streptozotocin.
In addition, it is evident that the expression of fewer rat GLUT2 mRNA molecules is required both in the case of alloxan (factor 2.8) and of streptozotocin (factor 1.4) to reduce the EC 50 value for their toxicity by 1 mmol/l than in the case of the expression of the human GLUT2 glucose transporter.
The results show that it is apparently the very low level of constitutive GLUT2 glucose transporter expression in the human beta cell [7, 8] rather than the inability of the human GLUT2 glucose transporter isoform to provide uptake of streptozotocin and alloxan into the intracellular compartment (Table 1) which is responsible for the extraordinarily high resistance of humans against the diabetogenic action of streptozotocin and alloxan. However, even if the human GLUT2 glucose transporter isoform would be more abundant in human pancreatic beta cells, the lower capacity for uptake of the toxins through the human GLUT2 glucose transporter isoform as compared to the rat transporter isoform would limit DOI 10.1007/s00125-003-1241-2
